New cell therapy aims to fight tough blood cancers
Disease control
Recruiting now
This study tests a new treatment called CTD402 for people aged 12 and older with T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (T-LBL) that has come back or not responded to other treatments. Participants receive one infusion of CTD402 and are monitored fo…
Phase: PHASE1, PHASE2 • Sponsor: BIOHENG THERAPEUTICS US LLC • Aim: Disease control
Last updated May 26, 2026 10:16 UTC